Pharsight

Drugs that contain Selumetinib Sulfate

1. Koselugo patents expiration

KOSELUGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(1 year, 1 month ago)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2024

(a month ago)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11813246 ASTRAZENECA Pharmaceutical composition
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

Family Patents